文献速递角膜与眼表疾病眼底病与葡萄膜炎眼外伤

英夫利西单抗结膜下持续递送在眼部碱烧伤后保护角膜和视网膜

Sustained Subconjunctival Delivery of Infliximab Protects the Cornea and Retina Following Alkali Burn to the Eye.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2017-01-01

本研究在6只荷兰带纹有色兔眼部碱烧伤后,立即结膜下植入载有85微克英夫利西单抗的聚合物递药系统(3只)或对照装置(3只),随访3个月。结果显示该装置耐受良好,与对照眼相比治疗眼角膜损伤更轻,且抑制角膜CD45和TNF-α表达及视网膜神经节细胞凋亡和视神经变性。

要点

  • 载有85微克英夫利西单抗的结膜下递药系统在兔碱烧伤后3个月内耐受良好。
  • 治疗眼较对照眼角膜损伤更轻,角膜CD45和TNF-α表达受抑制。
  • 治疗眼视网膜神经节细胞凋亡和视神经变性受抑制,药物渗透至结膜、角膜、虹膜和脉络膜。

核心结论

  • 这种低风险生物制剂递药系统改善角膜伤口愈合并提供视网膜神经保护,可能不仅适用于碱烧伤,也适用于其他炎症性手术操作如穿透性角膜移植和角膜假体植入。

研究设计与样本

  • 研究使用多孔聚二甲基硅氧烷/聚乙烯醇复合材料制备载有85微克英夫利西单抗的递药系统,6只荷兰带纹有色兔接受NaOH眼部碱烧伤,伤后立即结膜下植入抗TNF-α递药系统(3只兔)或对照递药系统(不含抗体,3只兔),随访摄影3个月。

主要发现

  • 3个月后装置被宿主良好耐受,与植入不含药物对照递药系统的眼相比,治疗眼角膜损伤更轻。
  • 与对照递药系统治疗眼相比,低剂量治疗抑制烧伤角膜中CD45和TNF-α表达,并抑制视网膜神经节细胞凋亡和视神经变性。
  • 免疫定位显示药物渗透至结膜、角膜、虹膜和脉络膜,植入3个月后递药系统中仍残留英夫利西单抗。

临床怎么用

  • 作者认为这种低风险生物制剂递药系统改善角膜伤口愈合并提供视网膜神经保护,可能不仅适用于碱烧伤,也适用于其他炎症性手术操作如穿透性角膜移植和角膜假体植入。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Tumor necrosis factor (TNF)-α is upregulated in eyes following corneal alkali injury and contributes to corneal and also retinal damage. Prompt TNF-α inhibition by systemic infliximab ameliorates retinal damage and improves corneal wound healing. However, systemic administration of TNF-α inhibitors carries risk of significant complications, whereas topical eye-drop delivery is hindered by poor ocular bioavailability and the need for patient adherence. This study investigates the efficacy of subconjunctival delivery of TNF-α antibodies using a polymer-based drug delivery system (DDS). METHODS: The drug delivery system was prepared using porous polydimethylsiloxane/polyvinyl alcohol composite fabrication and loaded with 85 μg of infliximab. Six Dutch-belted pigmented rabbits received ocular alkali burn with NaOH. Immediately after the burn, subconjunctival implantation of anti-TNF-α DDS was performed in three rabbits while another three received sham DDS (without antibody). Rabbits were followed with photography for 3 months. RESULTS: After 3 months, the device was found to be well tolerated by the host and the eyes exhibited less corneal damage as compared to eyes implanted with a sham DDS without drug. The low dose treatment suppressed CD45 and TNF-α expression in the burned cornea and inhibited retinal ganglion cell apoptosis and optic nerve degeneration, as compared to the sham DDS treated eyes. Immunolocalization revealed drug penetration in the conjunctiva, cornea, iris, and choroid, with residual infliximab in the DDS 3 months after implantation. CONCLUSIONS: This reduced-risk biologic DDS improves corneal wound healing and provides retinal neuroprotection, and may be applicable not only to alkali burns but also to other inflammatory surgical procedures such as penetrating keratoplasty and keratoprosthesis implantation.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Zhou C, Robert MC, Kapoulea V, et al. Sustained Subconjunctival Delivery of Infliximab Protects the Cornea and Retina Following Alkali Burn to the Eye. Invest Ophthalmol Vis Sci. 2017. PMID: 28114570. doi:10.1167/iovs.16-20339

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。